Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 2,650 shares at $60.00 ($159K) on 2022-01-05, disclosed to the SEC on 2022-01-07.
Open-market sale of $159k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |